LAS VEGAS–(BUSINESS WIRE)–Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQLAS VEGAS–(BUSINESS WIRE)–Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

LAS VEGAS–(BUSINESS WIRE)–Sagebrush Health Services, a nonprofit organization serving over 10,000 Nevada patients, has filed a lawsuit against Amgen Inc. (NASDAQ: AMGN), alleging that Amgen acted unlawfully by unilaterally terminating the sale of discounted drugs to Sagebrush’s clinics and improperly retracting millions of dollars in past discounts. These actions, Sagebrush maintains, temporarily prevented it from supplying its clinics with necessary medications from Amgen and other manufacturers.

Sagebrush filed the lawsuit in the California Superior Court in Ventura County, where Amgen is headquartered. The complaint asserts five causes of action against Amgen for violating California law and seeks to protect patients’ access to affordable care, particularly for the economically challenged and uninsured populations Sagebrush primarily serves.

The dispute centers on the 340B Drug Pricing Program, which allows eligible healthcare organizations (“covered entities”), such as Sagebrush’s clinics, to purchase outpatient drugs at significantly reduced prices. In its complaint, Sagebrush asks the court to order the return of not less than $7 million that Amgen improperly took from Sagebrush, and to award treble (triple) damages under California law, as well as punitive damages to “punish Amgen and deter future similar conduct.”

Lawsuit Alleges Amgen Ignored Established Federal Process

According to the complaint, the issue began nearly two years ago when Amgen unilaterally determined that Sagebrush was not an eligible entity under the 340B Program. The lawsuit asserts that Amgen, a $184 billion company, disregarded the established federal process for challenging a covered entity’s eligibility and instead took unilateral action.

The lawsuit also cites a letter from Amgen’s attorneys to a U.S. Senate committee, in which they acknowledged that “the 340B program is not designed to permit even this modest level of manufacturer oversight” and that manufacturers “are not equipped or permitted to police compliance.”

Statement from Sagebrush CEO

Guru Charan, the founder and CEO of Sagebrush Health Services, says, “We tried every step to avoid this lawsuit, but Amgen left us no choice. It’s vitally important that we continue to protect our patients’ access to the federal 340B Program and to the services it allows us to provide. We believe we’re standing up not only for our Nevada patients but also for those served by the additional 3,500 Section 318 grantees. These grantees provide health care to hundreds of thousands of people across the U.S. We must succeed to protect them as well.”

Notably, in March, the U.S. Department of Health and Human Services (HHS) confirmed Sagebrush’s eligibility as a covered entity under the 340B Program during a federal court hearing.

Sagebrush’s Commitment to Underserved Patients

Sagebrush Health is proud of its legacy of improving access for underserved populations. Its mission is to improve patients’ quality of life by using state-of-the-art technologies and evidence-based medicine, supported by its team of experienced providers and staff.

For instance, Sagebrush’s sexually transmitted infection (STI) program integrates education, screening, testing, and treatment services with specialized medical care, particularly for immunocompromised patients who face higher risks. This program provides critical services at a time of rising STI cases in the U.S.

Sagebrush reinvests savings from the 340B Program directly into vital community services, including free STI testing and prevention programs that are not covered by its grant funding. The lawsuit alleges that Amgen’s actions have severely curtailed these activities.

Contacts

MEDIA CONTACT:

Adam Shapiro

[email protected]
202-427-3603

Market Opportunity
FortuneHunters Logo
FortuneHunters Price(FORTUNE)
$0.000000094
$0.000000094$0.000000094
-32.85%
USD
FortuneHunters (FORTUNE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised

Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised

The post Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 20:26 While meme tokens like Pepe Coin and established networks such as Tron attract headlines, many investors are now searching for projects that combine innovation, revenue-sharing and real-world utility. BlockchainFX ($BFX), currently in presale at $0.024 ahead of an expected $0.05 launch, is quickly becoming one of the best cryptos to buy today. With $7m already secured and a unique model spanning multiple asset classes, it is positioning itself as a decentralised super app and a contender to surpass older altcoins. Early Presale Pricing Creates A Rare Entry Point BlockchainFX’s presale pricing structure has been designed to reward early participants. At $0.024, buyers secure a lower entry price than later rounds, locking in a cost basis more than 50% below the projected $0.05 launch price. As sales continue to climb beyond $7m, each new stage automatically increases the token price. This built-in mechanism creates a clear advantage for early investors and explains why the project is increasingly cited in “best presales to buy now” discussions across the crypto space. High-Yield Staking Model Shares Platform Revenue Beyond its presale appeal, BlockchainFX is creating a high-yield staking model that gives holders a direct share of platform revenue. Every time a trade occurs on its platform, 70% of trading fees flow back into the $BFX ecosystem: 50% of collected fees are automatically distributed to stakers in both BFX and USDT. 20% is allocated to daily buybacks of $BFX, adding demand and price support. Half of the bought-back tokens are permanently burned, steadily reducing supply. Rewards are based on the size of each member’s BFX holdings and capped at $25,000 USDT per day to ensure sustainability. This structure transforms token ownership from a speculative bet into an income-generating position, a rare feature among today’s altcoins. A Multi-Asset Platform…
Share
BitcoinEthereumNews2025/09/18 03:35
Yarm Explained: Turning Trust and Tweets into Yield

Yarm Explained: Turning Trust and Tweets into Yield

tl;dr: Yarm is a new platform by Mitosis and Kaito AI that turns social influence into onchain yield. Yappers earn Mindshare by posting…Continue reading on Coinmonks »
Share
Medium2025/09/18 14:43
Why Smart Talent Acquisition Leaders are Choosing Nearshore Over Offshore: The 2026 Talent Geography Playbook

Why Smart Talent Acquisition Leaders are Choosing Nearshore Over Offshore: The 2026 Talent Geography Playbook

Last quarter, I watched a director of engineering at a Series B startup spend three weeks trying to fill a temporary Senior Backend Engineer role. The rate? $89
Share
Techbullion2026/01/21 06:13